{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0062374\nAge: 66\nGender: Male\nSample ID: P-0062374-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Pancreatic Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 20.0%\n=============\nDNA Variants:\nBRAF c.1799_1801del (p.V600_K601delinsE) - in 15.00% of 137 reads\nCDKN2A c.151-2_152delinsC (p.X51_splice) - in 25.00% of 357 reads\nFOXL2 c.655C>T (p.Q219*) - in 8.00% of 225 reads\nSMAD4 c.355T>A (p.F119I) - in 10.00% of 153 reads\nTP53 c.817C>T (p.R273C) - in 16.00% of 384 reads\nTSC2 c.3308G>C (p.R1103T) - in 9.00% of 411 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"None specified based on molecular profile\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": \"BRAF V600_K601delinsE mutation, CDKN2A splice site deletion, TP53 R273C mutation, SMAD4 mutation, TSC2 R1103T mutation\",\n    \"Link to FDA-approved Label\": \"N/A\"\n  }\n}"
}